An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
NCT01220934 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 443
Last updated 2018-06-20
Summary
This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-04-16
- Primary Completion
- 2016-06-01
- Completion
- 2016-06-01
Countries
- Germany
Study Locations
More Related Trials
-
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
NCT04168931 ·Status: TERMINATED ·Phase: PHASE2
-
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
NCT02136836 ·Status: UNKNOWN
-
The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry
NCT02843412 ·Status: UNKNOWN
-
A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
NCT01839500 ·Status: COMPLETED
-
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
NCT04661150 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
NCT05993234 ·Status: RECRUITING
-
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia
NCT05892926 ·Status: COMPLETED
-
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
NCT01402401 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
NCT01774786 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02205047 ·Status: COMPLETED ·Phase: PHASE2
-
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
NCT02004769 ·Status: COMPLETED ·Phase: PHASE2
-
Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer
NCT02305043 ·Status: COMPLETED
-
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
NCT01641939 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study
NCT03368131 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
NCT05311189 ·Status: UNKNOWN ·Phase: PHASE2
-
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996 ·Status: RECRUITING
-
PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer
NCT01152853 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
NCT04309578 ·Status: COMPLETED ·Phase: PHASE2
-
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
NCT04014075 ·Status: COMPLETED ·Phase: PHASE2
-
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931 ·Status: RECRUITING ·Phase: PHASE2
-
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
NCT07332533 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
NCT04819971 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
NCT02240212 ·Status: COMPLETED ·Phase: PHASE1
-
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
NCT07334431 ·Status: RECRUITING ·Phase: PHASE1/PHASE2